U.S. Capital Wealth Advisors LLC Grows Stake in Sanofi (NASDAQ:SNY)

U.S. Capital Wealth Advisors LLC increased its holdings in shares of Sanofi (NASDAQ:SNY) by 46.3% in the 4th quarter, HoldingsChannel reports. The firm owned 7,951 shares of the company’s stock after acquiring an additional 2,515 shares during the quarter. U.S. Capital Wealth Advisors LLC’s holdings in Sanofi were worth $395,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of SNY. Rise Advisors LLC grew its stake in shares of Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after purchasing an additional 251 shares during the period. Salem Investment Counselors Inc. purchased a new position in Sanofi in the fourth quarter valued at $27,000. Venturi Wealth Management LLC raised its position in shares of Sanofi by 163.5% in the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after acquiring an additional 332 shares during the period. McIlrath & Eck LLC grew its position in shares of Sanofi by 143.3% during the 4th quarter. McIlrath & Eck LLC now owns 613 shares of the company’s stock valued at $30,000 after acquiring an additional 361 shares during the period. Finally, Farmers & Merchants Trust Co of Chambersburg PA increased its stake in shares of Sanofi by 115.6% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock valued at $37,000 after purchasing an additional 400 shares in the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have commented on SNY. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Finally, Morgan Stanley began coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $55.00.

Sanofi Price Performance

Sanofi stock opened at $49.57 on Wednesday. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.72. The firm has a market capitalization of $125.39 billion, a price-to-earnings ratio of 24.91, a PEG ratio of 1.37 and a beta of 0.61. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The company has a fifty day simple moving average of $47.92 and a 200-day simple moving average of $48.14.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be issued a $1.478 dividend. This represents a dividend yield of 2.98%. The ex-dividend date is Thursday, May 9th. This is a boost from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio (DPR) is currently 69.35%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.